NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 5,270,845 Shares

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 5,270,845 shares of NeuroPace stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

NeuroPace Trading Down 3.2 %

Shares of NPCE opened at $13.77 on Friday. NeuroPace, Inc. has a 52-week low of $5.45 and a 52-week high of $17.45. The business’s fifty day moving average is $12.49 and its 200-day moving average is $9.42. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The firm has a market cap of $411.01 million, a price-to-earnings ratio of -13.77 and a beta of 2.05.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NPCE. JPMorgan Chase & Co. lifted their price target on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. UBS Group started coverage on NeuroPace in a report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price target for the company. Finally, Wells Fargo & Company lifted their price objective on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.80.

Hedge Funds Weigh In On NeuroPace

Several hedge funds and other institutional investors have recently modified their holdings of NPCE. KCK LTD. bought a new stake in NeuroPace during the 4th quarter worth $58,981,000. Geode Capital Management LLC grew its position in NeuroPace by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 322,973 shares of the company’s stock worth $3,615,000 after acquiring an additional 5,781 shares during the last quarter. Northern Trust Corp grew its position in NeuroPace by 15.7% during the 4th quarter. Northern Trust Corp now owns 184,847 shares of the company’s stock worth $2,068,000 after acquiring an additional 25,035 shares during the last quarter. State Street Corp grew its position in NeuroPace by 9.1% during the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after acquiring an additional 12,912 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in NeuroPace during the 4th quarter worth $1,120,000. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.